5th Neuropsychiatric & Psychedelics Drug Development

With reports in depression and anxiety escalating and reaching critical levels, the urgency for developing effective, safe, and fast-acting therapeutics in psychiatry has never been greater. Advances in biomarker development, clinical endpoints, discovery platforms, and modelling have brought us to the precipice of breaking through the historical barriers in psychiatric and psychedelic drug development and into a new era of impactful treatments for this underserved community.

The 5th Neuropsychiatric & Psychedelic Drug Development Summit is the definitive forum to capitalize on decades of industry experience, clinical breakthroughs, and groundbreaking science to push pipeline progression and establish commercial success.

Join innovators from Bionomics, Cerevel, Delix, Gilgamesh, Opiant, Psilera, Xenon Pharmaceuticals and more in this exclusive event devoted to tackling industry challenges in the field of mental health medicines. From AI based discovery, to validated translational models moving to trial design, regulatory concerns and logistical affairs – explore the breadth of preclinical and clinical insights to be gained at this unmissable conference.

Tickets    https://go.evvnt.com/1252699-2?pid=2809 
Brochure https://go.evvnt.com/1252699-3?pid=2809 

Prices:
Conference + 2 Workshops - Drug Developer USD 3497.00
Conference + 1 Workshop - Drug Developer USD 3048.00
Conference Only - Drug Developer USD 2599.00
Conference + 2 Workshops - Vendors USD 4797.00
Conference + 1 Workshop - Vendors USD 4198.00
Conference Only - Vendors USD 3599.00

Speakers: Laxminarayan Bhat - Chief Executive Officer - Reviva Pharma, Alan Cross - Chief Scientific Officer - Psy Therapeutics, Errol De Souza - Executive Chairman - Bionomics, Murali Gopalakrishnan - Global Head Neuroscience Search & Evaluation - Abbvie, Zoe Hughes - Vice President & Head of Biology - Gilgamesh Pharmaceuticals, Christopher Kenney - Chief Medical Officer - Xenon Pharmaceuticals, Laszlo Kiss - Chief Business Officer - Gilgamesh Pharmaceuticals, James Lanthier - Chief Executive Officer - Mindset Pharma, Ronan Levy - Chief Executive Officer - Field Trip, Emeline Maillet - Chief Scientific Officer - Eastra Health, John McCorvy - Assistant Professor Medical - College Wisconsin, Michael McCully - Chief Executive Officer - Gate Neurosciences, David Olson - Chief Innovation Officer - Delix Therapeutics, John Renger - Chief Scientific Officer - Cerevel Therapeutics, Jacqueline von Salm - Co-Founder & Chief Scientific Officer - Psilera, Phil Skolnick - Chief Scientific Officer - Opiant Pharmaceuticals, Scott Thompson - Professor & Chair Department of Physiology - University of Maryland, Chris Witowski - Co-Founder & Chief Executive Officer - Psilera, George Papakostas - Professor - Massachusetts General Hospital, Seth Hopkins - Executive Director Translational Science - Sunovion Pharmaceuticals, Diego Pizzagalli - Professor of Psychiatry - Harvard Medical School, Monica Moller - Consultant Physician - Field Trip Health, Alberto Cruz-Martin - Assistant Professor - Boston University

Read More

View Less